NaturemiRI — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

NaturemiRI is an early-stage biotech leveraging its patent-pending Plasmid-based MicroRNA Inhibitor System (PMIS) to target miRNA biology. The platform enables the generation of transgenic animal models and stable cell lines for research and has advanced into therapeutic development for indications like cancer, tissue regeneration, and arthritis. Operating from Cambridge, the company appears to be privately held and pre-revenue, focusing on both research product sales and therapeutic pipeline advancement.

OncologyRegenerative MedicineArthritis

Technology Platform

Patent-pending Plasmid-based MicroRNA Inhibitor System (PMIS) for sustained inhibition of specific microRNAs via DNA plasmid delivery, enabling transgenic animal models and stable cell lines.

Opportunities

The PMIS platform's ability to create transgenic models addresses a high-value niche in research tools.

Therapeutically, durable miRNA inhibition via plasmid delivery could offer a significant dosing advantage over chronic oligonucleotide therapies in large markets like oncology and degenerative joint disease.

Risk Factors

Major risks include the unproven in vivo delivery and safety profile of therapeutic plasmids, intense competition from established oligonucleotide-based miRNA therapeutics, and reliance on external financing as a private, early-stage company.

Competitive Landscape

NaturemiRI competes in the miRNA space against well-funded firms like Regulus Therapeutics and MiNA Therapeutics that use synthetic oligonucleotides. Its plasmid-based approach is a key differentiator but faces steeper delivery challenges. In research tools, it competes with numerous miRNA inhibitor suppliers but offers a unique transgenic model capability.

More companies in Small Molecule Drugs →More companies in United States →